Wednesday, December 31, 2025 12/31/2025

Preclinical development of a novel therapeutic for Parkinson's disease

Award Number: R44NS124398
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Preclinical development of a novel therapeutic for Parkinson's disease - Project Summary Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, afflicting ~1 million Americans. Levodopa is the gold-standard symptomatic treatment for PD by elevating dopamine levels in the brain. Though the most effective treatment, prolonged levodopa use leads to 1) the debilitating side effect, levodopa-induced dyskinesia (LID), and 2) diminished levodopa efficacy which leads to fluctuations of PD symptoms, known as “wearing-off”. These concerns are two of the greatest unmet needs in PD and affect how doctors prescribe dosages and treatment options, impacting the efficacy of the necessary medications for PD. After 5 years of levodopa usage, 40% of PD patients will develop LID and/or fluctuations. Not only having a clinical impact, but PD patients with such complications require nearly $60,000 of additional therapeutics every year. Using Sinopia Biosciences’ computational platform, we studied gene expression changes due to levodopa administered to 6-OHDA lesioned PD-like mice. Applying our computational workflow, we identified a small molecule (SB-0107) that was selected based on: 1) having one of the top scores from our platform, 2) its novel mechanism of action, 3) previous clinical exposure to elderly patients, 4) its predicted CNS penetration properties, and 5) its potential for patent protection. Subsequently, we demonstrated the compound’s unique and potentially transformative pharmacology for treating both the symptoms of PD and complications of levodopa (i.e. LID). In both rodent and primate models, SB-0107 shows large effect sizes. Further, we observed in a cognitive deficit primate model of PD that SB-0107 improves performances in the tested cognitive tasks. Thus, SB-0107 represents a promising candidate for advancement to the clinic for PD. In this Fast-Track proposal, we will advance the compound by completing preclinical development studies for anticipation of IND submission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	8/14/2025	NON-COMPETING CONTINUATION	$0
2025	2024	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	5/29/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $1,282,299 )
2024	2024	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	3/1/2024	NON-COMPETING CONTINUATION	$1,282,299
2024	2021	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	9/10/2024	NEW	$0
														Subtotal = $1,282,299

Issue Date FY: 2023 ( Subtotal = $1,561,760 )
2023	2023	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	2	8/30/2023	SUPPLEMENT FOR EXPANSION	$99,900
2023	2023	SINOPIA BIOSCIENCES, INC.	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	3/20/2023	EXTENSION WITH OR WITHOUT FUNDS	$1,461,860
2023	2021	SINOPIA BIOSCIENCES, INC.	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	3/17/2023	NEW	$0
														Subtotal = $1,561,760

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	SINOPIA BIOSCIENCES, INC.	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	12/24/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $577,562 )
2021	2021	SINOPIA BIOSCIENCES, INC.	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/17/2021	NEW	$577,562
														Subtotal = $577,562

Grand Total All Awards = $3,421,621

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preclinical development of a novel therapeutic for Parkinson's disease

Award Number: R44NS124398

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer